While hypoglycemia and weight gain are well-known side effects of insulin therapy, we found that the most important barriers affecting the patient’s decision to start therapy were related to the impact of treatment on social life and misperceptions about the risks of insulin. The gene discussed is INS; the disease is Hypoglycemia.